A randomized phase II study comparing the efficacy and safety of the glyco-optimized anti-EGFR antibody tomuzotuximab against cetuximab in patients with recurrent and/or metastatic squamous cell cancer of the head and neck – the RESGEX study

BACKGROUND: The aim of the RESGEX study was to compare the efficacy and safety of the anti-epidermal growth factor receptor (anti-EGFR) antibody tomuzotuximab against cetuximab both in combination with chemotherapy in patients with recurrent and/or metastatic squamous cell cancer of the head and nec...

Descripción completa

Detalles Bibliográficos
Autores principales: Klinghammer, K., Fayette, J., Kawecki, A., Dietz, A., Schafhausen, P., Folprecht, G., Rottey, S., Debourdeau, P., Lavernia, J., Jacobs, A., Ahrens-Fath, I., Dietrich, B., Baumeister, H., Zurlo, A., Ochsenreither, S., Keilholz, U.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8424211/
https://www.ncbi.nlm.nih.gov/pubmed/34482179
http://dx.doi.org/10.1016/j.esmoop.2021.100242

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8424211/
https://www.ncbi.nlm.nih.gov/pubmed/34482179
http://dx.doi.org/10.1016/j.esmoop.2021.100242

Ejemplares similares